
Sources
Jump to the sources listed below for one of the following handouts:
​
April 2025
Herd Immunity: Do Vaccine Products Deliver?
-
Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines - Cox - 2004 - Scandinavian Journal of Immunology
onlinelibrary.wiley.com/doi/full/10.1111/j.0300-9475.2004.01382.x
-
Influenza vaccine effectiveness in the community and the household
europepmc.org/article/PMC/3693492
-
Increased Risk of Noninfluenza Respiratory Virus Infections Associated with Receipt of Inactivated Influenza Vaccine
pmc.ncbi.nlm.nih.gov/articles/PMC3404712
​ -
Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
-
CDC: About Tetanus
cdc.gov/tetanus/about/index.html
-
Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge
ncbi.nlm.nih.gov/pubmed/22532797
​ -
Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
nejm.org/doi/full/10.1056/NEJMoa054960
-
​Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak
nejm.org/doi/full/10.1056/NEJMoa1703309
​ -
Environmental factors potentially associated with mumps transmission in yeshivas during a mumps outbreak among highly vaccinated students: Brooklyn, New York, 2009-2010
ncbi.nlm.nih.gov/pubmed/23442590
-
Scientists Sue Merck Alleging MMR Vaccine Efficacy Fraud
ahrp.org/former-merck-scientists-sue-merck-alleging-mmr-vaccine-efficacy-fraud
​​
-
Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among re-vaccinees
ncbi.nlm.nih.gov/pubmed/9850133
​ -
The future of measles in highly immunized populations, a modeling approach
academic.oup.com/aje/article-abstract/120/1/39/98627​
-
The Re-Emergence of Measles in Developed Countries: Time to Develop the Next-Generation Measles Vaccines?
pmc.ncbi.nlm.nih.gov/articles/PMC3905323
-
Junk Science Week: Vaccinating the 'herd'
business.financialpost.com/fp-comment/junk-science-week-vaccinating-the-herd
​ -
Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
ncbi.nlm.nih.gov/pmc/articles/PMC3930734
-
Waning of Maternal Antibodies Against Measles, Mumps, Rubella, and Varicella in Communities with Contrasting Vaccination Coverage
academic.oup.com/jid/article-abstract/208/1/10/796786?redirectedFrom=fulltext
-
Scientists pinpoint mutations responsible for ineffectiveness of 2014-2015 flu vaccine
sciencedaily.com/releases/2015/06/150625130251
​ -
Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North America outbreak
ncbi.nlm.nih.gov/pubmed/22423127
​ -
2013 Measles Outbreak: A failing vaccine, not a Failure to vaccinate
greenmedinfo.com/blog/2013-measles-outbreak-failing-vaccine-not-failure-vaccinate1
-
Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons
ncbi.nlm.nih.gov/pubmed/8053748
​ -
Tdap Vaccine Effectiveness in Adolescents During the 2012 Washington State Pertussis Epidemic
publications.aap.org/pediatrics/article-abstract/135/6/981/75791/Tdap-Vaccine-Effectiveness-in-Adolescents-During
-
Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
ncbi.nlm.nih.gov/pmc/articles/PMC3930734
​ -
Waning of Maternal Antibodies Against Measles, Mumps, Rubella, and Varicella in Communities With Contrasting Vaccination Coverage
academic.oup.com/jid/article-abstract/208/1/10/796786
-
Scientists pinpoint mutations responsible for ineffectiveness of 2014-2015 flu vaccine
sciencedaily.com/releases/2015/06/150625130251
​
-
Tdap Vaccine Effectiveness in Adolescents During the 2012 Washington State Pertussis Epidemic
publications.aap.org/pediatrics/article-abstract/135/6/981/75791/Tdap-Vaccine-Effectiveness-in-Adolescents-During
-
​Influenza vaccine effectiveness in the community and the household
pubmed.ncbi.nlm.nih.gov/23413420
-
Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine
pubmed.ncbi.nlm.nih.gov/22423139
-
​Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada
pubmed.ncbi.nlm.nih.gov/20386731
-
Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus
pubmed.ncbi.nlm.nih.gov/19538996
​ -
Comparison of VAERS fetal-loss reports during three consecutive influenza seasons
pmc.ncbi.nlm.nih.gov/articles/PMC3888271
-
Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
pubmed.ncbi.nlm.nih.gov/24277828
-
​Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population
pubmed.ncbi.nlm.nih.gov/2278542
​ -
CDC: Causes of Tetanus and How It Spreads
cdc.gov/tetanus/causes/index.html
-
​Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
pubmed.ncbi.nlm.nih.gov/24277828
-
​Vaccine waning and mumps re-emergence in the United States
pmc.ncbi.nlm.nih.gov/articles/PMC5899613 -
Former Merck Scientists Sue Merck Alleging MMR Vaccine Efficacy Fraud – Alliance for Human Research Protection
ahrp.org/former-merck-scientists-sue-merck-alleging-mmr-vaccine-efficacy-fraud
-
Civil Action No. 10-4374, Relators Stephen A. Krahling and Joan A. Wlochowski (“Plaintiffs”) bring this qui tam action in accordance with the False Claims Act (“FCA”), pursuant to 31 U.S.C. §§ 3729-33. Relators allege that their former employer, Defendant Merck & Co., Inc. (“Merck”) fraudulently misled the government and omitted, concealed, and adulterated material information regarding the efficacy of its mumps vaccine in violation of the FCA.
rescuepost.com/files/59-opinion.pdf
-
Merck Has Some Explaining To Do Over Its MMR Vaccine Claims
huffpost.com/archive/ca/entry/merck-has-some-explaining-to-do-over-its-mmr-vaccine-claims_b_5881914
-
​The Re-Emergence of Measles in Developed Countries: Time to Develop the Next-Generation Measles Vaccines?
pmc.ncbi.nlm.nih.gov/articles/PMC3905323
-
CDC: ​About Hepatitis B
cdc.gov/hepatitis-b/about/index.html
​
-
Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community
pnas.org/doi/10.1073/pnas.1716561115
-
Loss of Vaccine-Induced Immunity to Varicella over Time
nejm.org/doi/full/10.1056/nejmoa064040
-
Successes and Challenges in Varicella Vaccine
pmc.ncbi.nlm.nih.gov/articles/PMC3991154
-
​Vaccine Types according to HHS.gov
hhs.gov/immunization/basics/types/index.html
May 2023
COVID-19 Vaccine - What You Should Know
-
Doshi P. Will covid-19 vaccines save lives? Current trials aren’t designed to tell us.
bmj.com/content/371/bmj.m4037
-
Haseltine WA. Covid-19 vaccine protocols reveal that trials are designed to suc- ceed. Forbes, September 23, 2020.
forbes.com/sites/williamhasel- tine/2020/09/23/covid-19-vaccine-protocols-reveal-that-trials-are- designed-to-suc- ceed
-
Brownstein D, Ng R, Rowen R et al. A novel approach to treating COVID-19 using nutritional and oxidative therapies. Science, Public Health Policy, and the Law 2020;2:4-22
ozonewithoutborders.ngo/wp-content/ uploads/2020/07/Novel-Approach-to- Covid-19.pdf
-
Jackson LA, Anderson EJ, Rouphael NG et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. New England Journal of Medicine.
nejm.org/doi/full/10.1056/NEJMoa2022483
-
Allen A, Szabo L. NIH “very concerned” about serious side effect in coronavirus vaccine trial. Scientific American, September 15, 2020.
scientificamerican.com/ article/nih-very-concerned-about-serious-side-effect-in- coronavirus-vaccine-trial
-
Mayer A. Leading COVID vaccine candidates plagued by safety concerns. The Defender, November 13, 2020
childrenshealthdefense.org/defender/covid-vaccine-can- didates-safety-concerns
-
U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, October 22, 2020 Meeting Presentation, slide #16
green- medinfo.com/blog/covid-19-vaccine-bombshell-fda- documents-reveal-death-21-seri- ous-conditions-possi1
-
Reals T. U.K. warns against giving Pfizer vaccine to people prone to severe allergic reactions. CBS News, December 9, 2020
cbsnews.com/amp/news/ covid-vaccine-pfizer-shot-uk-warning-people-with- history-of-significant-allergic-reactions
-
fda.gov/media/144245/download page 42
-
Public Readiness and Emergency Preparedness Act. COVID-19 PREP Act Declarations
phe.gov/Preparedness/legal/prepact
-
Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. Journal of Translational Autoimmunity.
ncbi.nlm.nih.gov/pmc/articles/PMC7142689
-
Khemlani A. Fauci: Early COVID-19 vaccines will only prevent symptoms, not block the virus. Yahoo! Finance, October 26, 2020
finance.yahoo.com/news/fauci-vaccines-will-only-prevent-symptoms-not-block-the-virus-195051568.html
-
Scipioni J. Dr. Fauci says masks, social distancing will still be needed after a Covid-19 vaccine—here’s why. CNBC, November 16, 2020
cnbc.com/2020/11/16/ fauci-why-still-need-masks-social-distancing-after-covid-19-vaccine.html
-
Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. Updated September 10, 2020
cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html
-
Petition/motion for administrative/regulatory action regarding confirmation of efficacy end points and use of data in connection with the following clinical trials. Dr. Wolfgang Wodarg and Dr. Michael Yeadon, petitioners. Filed with European Medicines Agency, December 1, 2020
healthimpactnews.com/wp- content/uploads/ sites/2/2020/12/Wodarg_Yeadon_EMA_Petition_Pfizer_Trial_FINAL_01DEC2020_ EN_unsigned_with_Exhibits.pdf
-
AMA, Ethics, Informed Consent
ama-assn.org/delivering-care/ethics/informed-consent
-
Int J Clin Pract. 2020 Oct 28 : e13795., PDF
ncbi.nlm.nih.gov/pmc/articles/PMC7645850/pdf/IJCP-9999-e13795.pdf
-
Front. Microbiol., 05 December 2018
frontiersin.org/articles/10.3389/fmicb.2018.02991
-
PNAS.org April 14, 2020 117 (15) 8218-8221
pnas.org/content/117/15/8218
-
JCI Insight February 21, 2019
insight.jci.org/articles/view/123158


August 2019
Vaccine Schedule Comparison Post Card
-
54% of our children have chronic illness
ncbi.nlm.nih.gov/pubmed/21570014?fbclid=IwAR1icXzyPrjy0E9Kr4EqiWMEhAA-4Na38xC-e5HOA835ggPeuIIIF_as71U
​ -
1 in 36 autism
cdc.gov/nchs/products/databriefs/db291.htm
and
askdrsears.com/topics/autism/autism-rate-jumps-1-36-children-1-28-boys?fbclid=IwAR27M4lUFO7AXaYQdZRcE-I-BenZQ4PtXV1LErjsYjGjFVfdxmYhAZdxHx4
​ -
8% or 1 in 12 have food allergies
pediatrics.aappublications.org/content/142/6/e20181235
​ -
14% are in special education
nces.ed.gov/programs/coe/indicator_cgg.asp?fbclid=IwAR3PllXZ9cvlgJUfYym_nlM1Vqz4lKK_Gu8Wyr8pmEZtTrPvU0mORqYV1c8
​ -
1 in 285 will be diagnosed with cancer
acco.org/wp-content/uploads/2014/11/ACS-Special-Report-2014.pdf
​ -
1 in 26 will develop epilepsy
aesnet.org/for_patients/facts_figures?fbclid=IwAR2jVD3yKJHYfNQayUDfdCnQZlaS4yiu-_DUBmgkS8GCuGVvDzVUI3LLvnQ#Eight
-
1 in 12 have asthma
aafa.org/asthma-facts
-
1 in 5 have learning disabilities
ncld.org/archives/blog/the-state-of-ld-understanding-the-1-in-5


